
Pharmaceutical
Novartis buys Tourmaline Bio in $1.4 billion deal, adding heart drug pacibekitug
Novartis announced Tuesday that it will acquire U.S.-based Tourmaline Bio in a deal valued at roughly $1.4 billion, as the Swiss pharmaceutical giant seeks to expand its cardiovascular drug portfolio. Under the agreement, Novartis will purchase Tourmaline Bio shares at $48 each, valuing the clinical-stage biopharma company